Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene

  • Technology appraisal guidance
  • TA296
  • Published: 

This guideance has been updated and replaced by NICE technology appraisal guidance 422.